RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:300903

ALK-negative anaplastic large cell lymphoma

low confidenceSubtype of disorder

Also known as: ALK- ALCL · ALK- anaplastic large cell lymphoma

Publications

2,173

Trials

25

Interventional, condition-specific

Researchers

1,412

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the lack of expression of a protein called anaplastic lymphoma kinase (ALK).

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

ALCL, ALK- · anaplastic large cell lymphoma, ALK-negative

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    2,173 matched papers (1,487 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    25 matched on ClinicalTrials.gov (6 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

2,173

2,173 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

2,173 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

1,487 in the last 10 years · low confidence

Phrase hits: 2,173 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,412

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Li S10 papers · 2026

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    Papers in Europe PMC
  2. 02
    Medeiros LJ9 papers · 2026

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    Papers in Europe PMC
  3. 03
    Lamant L8 papers · 2026

    Pathology Department, Institut Universitaire du Cancer-Oncopole, CHU Toulouse, Labex TOUCAN, Toulouse, France.

    Papers in Europe PMC
  4. 04
    Xu J8 papers · 2026

    Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

    Papers in Europe PMC
  5. 05
    Zhang L7 papers · 2026

    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China.

    Papers in Europe PMC
  6. 06
    Babin L6 papers · 2026

    CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Univ Toulouse, CNRS, INSERM, 31037, Toulouse, France.

    Papers in Europe PMC
  7. 07
    Liu W6 papers · 2024

    Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province.

    Papers in Europe PMC
  8. 08
    Liu Y6 papers · 2026

    Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China.

    Papers in Europe PMC
  9. 09
    Meggetto F6 papers · 2026

    CRCT (Cancer Research Center of Toulouse), UMR-1037, UMR-5071, Institut Universitaire du Cancer, Univ Toulouse, CNRS, INSERM, 31037, Toulouse, France. fabienne.meggetto@inserm.fr.

    Papers in Europe PMC
  10. 10
    Miranda RN6 papers · 2026

    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

25

interventional trials for this specific condition

25 interventional trials matched this specific condition name; 6 currently recruiting in our sample. 160 trials are registered for anaplastic large cell lymphoma, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

25 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 95.1th percentile).

low confidence · 95.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

25 interventional trials matched after quoted-phrase search and title/condition post-filter.

Broader category: anaplastic large cell lymphoma

160

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Observational and natural-history studies

3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"ALK-negative anaplastic large cell lymphoma" OR "ALK- ALCL" OR "ALK- anaplastic large cell lymphoma" OR "ALCL, ALK-" OR "anaplastic large cell lymphoma, ALK-negative"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"ALK-negative anaplastic large cell lymphoma" OR "ALK- ALCL" OR "ALK- anaplastic large cell lymphoma" OR "ALCL, ALK-" OR "anaplastic large cell lymphoma, ALK-negative"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 25 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"anaplastic large cell lymphoma"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2173) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T12:45:41.963Z